ES012 / Elpiscience - LARVOL DELTA

Siglec15 induces monocyte apoptosis and an Siglec15 antibody ES012 reverses myeloid cells-driven immunosuppression (SITC 2022) - "Conclusions In summary, we found that siglec15 has a major effect on myeloid cells (inducing monocyte apoptosis and inhibiting monocyte activation) and an indirect inhibitory effect on T cell function. Based on this newly discovered S15 biology, we have developed a potent, functional anti-Siglec15 mAb ES012 that has great potential to reverse immune suppression in the TME to promote anti-tumor immunity."

Oncology • CD14 • CD86 • CSF1 • SIGLEC1 • SIGLEC15

Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting (Businesswire) - "Elpiscience Biopharmaceuticals...presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting....Abstract No.: 1401...Highlight: (i) ES012 is a high affinity anti-SIGLEC15 monoclonal antibody; (ii) ES012 can rescue monocyte apoptosis and inhibit T cells by SIGLEC15; (iii) ES012 showed superior anti-tumor efficacy and better PK profile than benchmark antibody in preclinical model."

Preclinical • Oncology

Elpiscience Announces Five Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting (Businesswire) - "Elpiscience Biopharmaceuticals...announced it will have five poster presentations at the SITC 2022 Annual Meeting being held in Boston, Massachusetts from November 8-12. The posters will highlight studies on five innovative molecules including anti-SIRPα monoclonal antibody ES004, anti-LAG3 monoclonal antibody ES005, anti-LILRB2 monoclonal antibody ES009, anti-SIGLEC15 antibody ES012, and PD-L1/SIRPα bispecific macrophage engager ES019."

Preclinical • Oncology